• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于噬排相关基因表达水平的胶质母细胞瘤预后模型的建立。

Development of a prognostic model for glioblastoma multiforme based on the expression levels of efferocytosis-related genes.

机构信息

Department of Neurosurgery, Qilu Hospital of Shandong University and Institute of Brain and Brain-Inspired Science, Shandong University, Shandong, Jinan 250012, China.

Department of Radiation Oncology, Qilu Hospital of Shandong University, Shandong, Jinan 250012, China.

出版信息

Aging (Albany NY). 2023 Dec 29;15(24):15578-15598. doi: 10.18632/aging.205422.

DOI:10.18632/aging.205422
PMID:38159261
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10781462/
Abstract

Glioblastoma multiforme (GBM) is one of the most common and aggressive brain tumors. The microenvironment of GBM is characterized by its highly immunosuppressive nature with infiltration of immunosuppressive cells and the expression levels of cytokines. Efferocytosis is a biological process in which phagocytes remove apoptotic cells and vesicles from tissues. Efferocytosis plays a noticeable function in the formation of immunosuppressive environment. This study aimed to develop an efferocytosis-related prognostic model for GBM. The bioinformatic methods were utilized to analyze the transcriptomic data of GBM and normal samples. Clinical and RNA-seq data were sourced from TCGA database comprising 167 tumor samples and 5 normal samples, and 167 tumor samples for which survival information was available. Transcriptomic data of 1034 normal samples were collected from the Genotype-Tissue Expression (GTEx) database as a control sample supplement to the TCGA database. In the end, 167 tumor samples and 1039 normal samples were obtained for transcriptome analysis. Efferocytosis-related differentially expressed genes (ERDEGs) were obtained by intersecting 7487 differentially expressed genes (DEGs) between GBM and normal samples along with 1189 hub genes. Functional enrichment analyses revealed that ERDEGs were mainly involved in cytokine-mediated immune responses. Moreover, 9 prognosis-related genes (PRGs) were identified by the least absolute shrinkage and selection operator (LASSO) regression analysis, and a prognostic model was therefore developed. The nomogram combining age and risk score could effectively predict GBM patients' prognosis. GBM patients in the high-risk group had higher immune infiltration, invasion, epithelial-mesenchymal transition, angiogenesis scores and poorer tumor purity. In addition, the high-risk group exhibited higher half maximal inhibitory concentration (IC50) values for temozolomide, carmustine, and vincristine. Expression analysis indicated that PRGs were overexpressed in GBM cells. PDIA4 knockdown reduced efferocytosis . In summary, the proposed prognostic model for GBM based on efferocytosis-related genes exhibited a robust performance.

摘要

胶质母细胞瘤(GBM)是最常见和侵袭性最强的脑肿瘤之一。GBM 的微环境以其高度免疫抑制特性为特征,包括免疫抑制细胞的浸润和细胞因子的表达水平。吞噬作用是一种生物过程,其中吞噬细胞从组织中清除凋亡细胞和囊泡。吞噬作用在形成免疫抑制环境中起着显著的作用。本研究旨在为 GBM 开发一种与吞噬作用相关的预后模型。利用生物信息学方法分析 GBM 和正常样本的转录组数据。临床和 RNA-seq 数据来自 TCGA 数据库,包括 167 个肿瘤样本和 5 个正常样本,以及 167 个具有生存信息的肿瘤样本。从 TCGA 数据库中获取了 1034 个正常样本的转录组数据,作为对 TCGA 数据库的补充。最终,获得了 167 个肿瘤样本和 1039 个正常样本进行转录组分析。通过 intersecting 7487 个 GBM 和正常样本之间差异表达基因(DEGs)和 1189 个枢纽基因,获得了与吞噬作用相关的差异表达基因(ERDEGs)。功能富集分析表明,ERDEGs 主要参与细胞因子介导的免疫反应。此外,通过最小绝对收缩和选择算子(LASSO)回归分析确定了 9 个预后相关基因(PRGs),因此建立了一个预后模型。结合年龄和风险评分的列线图可以有效地预测 GBM 患者的预后。风险评分较高的 GBM 患者具有更高的免疫浸润、侵袭、上皮-间充质转化、血管生成评分和较差的肿瘤纯度。此外,高风险组的替莫唑胺、卡莫司汀和长春新碱的半最大抑制浓度(IC50)值更高。表达分析表明,PRGs 在 GBM 细胞中过表达。PDIA4 敲低降低了吞噬作用。总之,基于吞噬作用相关基因的 GBM 预后模型表现出良好的性能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/e8e40799752f/aging-15-205422-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/b7b4c03479a6/aging-15-205422-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/3502c5d32ebd/aging-15-205422-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/6365f479f9fe/aging-15-205422-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/914abf4007f9/aging-15-205422-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/107e60576fec/aging-15-205422-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/3813f8a0337e/aging-15-205422-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/9a44ccd40b9c/aging-15-205422-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/a966fe7599a1/aging-15-205422-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/e8e40799752f/aging-15-205422-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/b7b4c03479a6/aging-15-205422-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/3502c5d32ebd/aging-15-205422-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/6365f479f9fe/aging-15-205422-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/914abf4007f9/aging-15-205422-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/107e60576fec/aging-15-205422-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/3813f8a0337e/aging-15-205422-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/9a44ccd40b9c/aging-15-205422-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/a966fe7599a1/aging-15-205422-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab5e/10781462/e8e40799752f/aging-15-205422-g009.jpg

相似文献

1
Development of a prognostic model for glioblastoma multiforme based on the expression levels of efferocytosis-related genes.基于噬排相关基因表达水平的胶质母细胞瘤预后模型的建立。
Aging (Albany NY). 2023 Dec 29;15(24):15578-15598. doi: 10.18632/aging.205422.
2
Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma.基于铜死亡相关基因的系统分析鉴定出铁氧还蛋白 1 是胶质母细胞瘤的免疫调节剂和治疗靶点。
BMC Cancer. 2023 Dec 19;23(1):1249. doi: 10.1186/s12885-023-11727-z.
3
Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.通过单细胞和批量 RNA 测序的综合分析,开发和验证一种基于自然杀伤 T 细胞标记基因的预后模型,用于预测胶质母细胞瘤的预后和表征免疫状态。
Funct Integr Genomics. 2023 Aug 31;23(3):286. doi: 10.1007/s10142-023-01217-7.
4
Interaction, immune infiltration characteristics and prognostic modeling of efferocytosis-related subtypes in glioblastoma.胶质母细胞瘤中细胞吞噬相关亚型的相互作用、免疫浸润特征和预后建模。
BMC Med Genomics. 2023 Oct 18;16(1):248. doi: 10.1186/s12920-023-01688-4.
5
Pyroptosis-related prognosis model, immunocyte infiltration characterization, and competing endogenous RNA network of glioblastoma.胶质母细胞瘤中与细胞焦亡相关的预后模型、免疫细胞浸润特征和竞争内源性 RNA 网络。
BMC Cancer. 2022 Jun 3;22(1):611. doi: 10.1186/s12885-022-09706-x.
6
Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.系统识别、开发和验证涉及胶质母细胞瘤肿瘤免疫微环境的预后生物标志物。
J Cell Physiol. 2021 Jan;236(1):507-522. doi: 10.1002/jcp.29878. Epub 2020 Jun 22.
7
A novel Foxp3-related immune prognostic signature for glioblastoma multiforme based on immunogenomic profiling.基于免疫基因组分析的胶质母细胞瘤新型 Foxp3 相关免疫预后标志物。
Aging (Albany NY). 2021 Jan 10;13(3):3501-3517. doi: 10.18632/aging.202282.
8
Identification and validation of a novel robust glioblastoma prognosis model based on bioinformatics.基于生物信息学的新型稳健性胶质母细胞瘤预后模型的鉴定与验证
Heliyon. 2024 Sep 3;10(18):e37374. doi: 10.1016/j.heliyon.2024.e37374. eCollection 2024 Sep 30.
9
The neutrophil extracellular traps-related gene signature predicts the prognosis of glioblastoma multiforme.中性粒细胞胞外诱捕网相关基因特征可预测多形性胶质母细胞瘤的预后。
Folia Neuropathol. 2024;62(1):59-75. doi: 10.5114/fn.2023.132980.
10
Histone acetylation gene-based biomarkers as novel markers of the immune microenvironment in glioblastoma.基于组蛋白乙酰化基因的生物标志物作为胶质母细胞瘤免疫微环境的新型标志物
J Gene Med. 2023 Oct;25(10):e3511. doi: 10.1002/jgm.3511. Epub 2023 Apr 25.

引用本文的文献

1
The Correlation Patterns of miRNA Expression with Targeted mRNA Transcripts in Glioma Patients with Wild-Type and Mutated Isocitrate Dehydrogenase (IDH) Genotypes.野生型和异柠檬酸脱氢酶(IDH)基因突变型胶质瘤患者中miRNA表达与靶向mRNA转录本的相关性模式
Acta Naturae. 2024 Jul-Sep;16(3):38-45. doi: 10.32607/actanaturae.27363.

本文引用的文献

1
Interaction, immune infiltration characteristics and prognostic modeling of efferocytosis-related subtypes in glioblastoma.胶质母细胞瘤中细胞吞噬相关亚型的相互作用、免疫浸润特征和预后建模。
BMC Med Genomics. 2023 Oct 18;16(1):248. doi: 10.1186/s12920-023-01688-4.
2
Protein disulfide-isomerase A4 confers glioblastoma angiogenesis promotion capacity and resistance to anti-angiogenic therapy.蛋白二硫键异构酶 A4 赋予胶质母细胞瘤血管生成促进能力和抗血管生成治疗耐药性。
J Exp Clin Cancer Res. 2023 Mar 30;42(1):77. doi: 10.1186/s13046-023-02640-1.
3
CD8+ T cell-Dependent Remodeling of the Tumor Microenvironment Overcomes Chemoresistance.
CD8+ T 细胞依赖性的肿瘤微环境重塑克服化疗耐药性。
Cancer Immunol Res. 2023 Mar 1;11(3):320-338. doi: 10.1158/2326-6066.CIR-22-0356.
4
Pediatric Central Nervous System Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.儿童中枢神经系统肿瘤,2023 年第 2 版,NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2022 Dec;20(12):1339-1362. doi: 10.6004/jnccn.2022.0062.
5
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019.美国 2015-2019 年确诊的原发性脑和其他中枢神经系统肿瘤 CBTRUS 统计报告。
Neuro Oncol. 2022 Oct 5;24(Suppl 5):v1-v95. doi: 10.1093/neuonc/noac202.
6
Pyroptosis-related prognosis model, immunocyte infiltration characterization, and competing endogenous RNA network of glioblastoma.胶质母细胞瘤中与细胞焦亡相关的预后模型、免疫细胞浸润特征和竞争内源性 RNA 网络。
BMC Cancer. 2022 Jun 3;22(1):611. doi: 10.1186/s12885-022-09706-x.
7
Drugging the efferocytosis process: concepts and opportunities.药物干预细胞吞噬作用的过程:概念与机遇
Nat Rev Drug Discov. 2022 Aug;21(8):601-620. doi: 10.1038/s41573-022-00470-y. Epub 2022 Jun 1.
8
Recognition of a Novel Gene Signature for Human Glioblastoma.识别人类脑胶质母细胞瘤的新型基因特征。
Int J Mol Sci. 2022 Apr 9;23(8):4157. doi: 10.3390/ijms23084157.
9
Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively.蛋白二硫键异构酶 A3 是癌症强有力的预后生物标志物,并能有效预测免疫治疗反应效果。
Front Immunol. 2022 Mar 25;13:837512. doi: 10.3389/fimmu.2022.837512. eCollection 2022.
10
Immunotherapy of glioblastoma: Recent advances and future prospects.胶质母细胞瘤的免疫治疗:最新进展与未来展望。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2055417. doi: 10.1080/21645515.2022.2055417. Epub 2022 Mar 28.